Loading
Celecoxib / Minocycline / Treatment Resistant Depression (TRD) · Interventional Study
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed randomized controlled trial registry record comparing minocycline and celecoxib as adjunctive treatments for treatment-resistant major depressive disorder over 12 weeks. No outcome results are posted in this registry entry; efficacy and safety data remain unreported and the trial's conclusions cannot be evaluated.
Interventional, Randomized, Parallel, Single masking, Treatment purpose. Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD); age from 18 Years; to 65 Years. Intervention: Group Minocycline. Compared with: Group Celecoxib — Active Comparator. n = 78. 1 site: Pakistan.
This is a completed randomized controlled trial registry record comparing minocycline and celecoxib as adjunctive treatments for treatment-resistant major depressive disorder over 12 weeks. No outcome results are posted in this registry entry; efficacy and safety data remain unreported and the trial's conclusions cannot be evaluated.
No efficacy or safety results are reported in this registry entry; trial completion status does not confirm results have been posted elsewhere.
The source did not state who this applies to in practice.
This is a completed registry record reporting a planned RCT design and enrollment, but no results are posted; outcome data cannot be assessed.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07804979). This is a study registration, not published results. Lead sponsor: Lahore General Hospital. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 78 participants (ACTUAL). Conditions: Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD). Interventions: DRUG: Minocycline; DRUG: Celecoxib. Primary outcome measures: Change in Hamilton Depression Rating Scale (HAM-D) Score , Baseline and 12 weeks. Brief summary: This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder. Treatment-resistant depression was defined as depression that had not adequately improved despite appropriate previous antidepressant treatment. A total of 78 patients aged 18-65 years were enrolled from the Psychiatry Department of Lahore General Hospital, Lahore, and were randomly assigned to two treatment groups. One group received minocycline 100 mg twice daily with fluoxetine 20-40 mg, while the other group received celecoxib 200 mg twice daily with fluoxetine 20-40 mg. Treatment was continued for 12 weeks. Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline and during follow-up. The main outcome was the change in HAM-D score from baseline to the end of treatment. Treatment response was defined as a reduction of at least 50% in the HAM-D score, while remission was defined as a final HAM-D score of 7 or lower. The study was designed to test whether adding minocycline or celecoxib to fluoxetine would reduce depressive symptoms in treatment-resistant major depressive disorder and whether the degree of improvement differed between the two adjunctive treatments.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.